PharmaShots | Incisive News in 3 Shots

Subscribe Now

Follicular

$Incyte and MorphoSys Report First Patient Dosing in P-III inMIND Study for Relapsed or Refractory Follicular or Marginal Zone Lymphoma$

Incyte and MorphoSys Report First Patient Dosing in P-III inMIND Study for Relapsed or Refractory Follicular or Marginal Zone Lymp...

April 20, 2021

TG Therapeutics' Ukoniq (umbralisib) Receives the US FDA's Approval for R/R Marginal Zone Lymphoma and Follicular Lymphoma

TG Therapeutics' Ukoniq (umbralisib) Receives the US FDA's Approval for R/R Marginal Zone Lymphoma and Follicular Lymphoma

February 2, 2021

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us